Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Mirabegron: A Review in Overactive Bladder Syndrome

Mirabegron: A Review in Overactive Bladder Syndrome The first-in-class β3-adrenoceptor agonist mirabegron is indicated in the EU (Betmiga™), Japan (Betanis™) and several other countries for the management of overactive bladder (OAB) syndrome. Evidence for its use in this setting includes several large phase 3 trials. Compared with placebo, oral mirabegron for 12 weeks reduced the frequency of micturition and generally also that of incontinence, with other benefits including reduced urgency, increased void volume and improved health related quality-of-life (HR-QOL). Mirabegron comparisons versus tolterodine are descriptive; however, in a 12-week powered comparison versus solifenacin in patients dissatisfied with antimuscarinic efficacy, mirabegron did not demonstrate noninferiority in reducing micturition frequency or significantly differ in terms of improving other urinary symptoms. Urinary and HR-QOL benefits of mirabegron were sustained over up to 52 weeks of treatment and the drug was generally well tolerated, with a numerically lower incidence of dry mouth than antimuscarinics. Real-world data support the trial findings and indicate possible persistence and adherence benefits for mirabegron over antimuscarinics. Mirabegron use is not generally restricted by patient age, sex or antimuscarinic treatment status, although data in men (from a phase 4 study and phase 3 trial subanalyses) are variable; additional studies in older and male OAB patients are awaited with interest. Although further longer-term efficacy and tolerability data would be beneficial, current clinical evidence indicates that mirabegron provides an alternative to antimuscarinics for the management of OAB in adults, including those for whom antimuscarinics have proven unsuitable. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs Springer Journals

Mirabegron: A Review in Overactive Bladder Syndrome

Deeks, Emma
Drugs , Volume 78 (8) – Jun 4, 2018
Download PDF
12 pages

Loading next page...
 
/lp/springer_journal/mirabegron-a-review-in-overactive-bladder-syndrome-02rNhWwGVx
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
0012-6667
eISSN
1179-1950
DOI
10.1007/s40265-018-0924-4
pmid
29869204
Publisher site
See Article on Publisher Site

Abstract

The first-in-class β3-adrenoceptor agonist mirabegron is indicated in the EU (Betmiga™), Japan (Betanis™) and several other countries for the management of overactive bladder (OAB) syndrome. Evidence for its use in this setting includes several large phase 3 trials. Compared with placebo, oral mirabegron for 12 weeks reduced the frequency of micturition and generally also that of incontinence, with other benefits including reduced urgency, increased void volume and improved health related quality-of-life (HR-QOL). Mirabegron comparisons versus tolterodine are descriptive; however, in a 12-week powered comparison versus solifenacin in patients dissatisfied with antimuscarinic efficacy, mirabegron did not demonstrate noninferiority in reducing micturition frequency or significantly differ in terms of improving other urinary symptoms. Urinary and HR-QOL benefits of mirabegron were sustained over up to 52 weeks of treatment and the drug was generally well tolerated, with a numerically lower incidence of dry mouth than antimuscarinics. Real-world data support the trial findings and indicate possible persistence and adherence benefits for mirabegron over antimuscarinics. Mirabegron use is not generally restricted by patient age, sex or antimuscarinic treatment status, although data in men (from a phase 4 study and phase 3 trial subanalyses) are variable; additional studies in older and male OAB patients are awaited with interest. Although further longer-term efficacy and tolerability data would be beneficial, current clinical evidence indicates that mirabegron provides an alternative to antimuscarinics for the management of OAB in adults, including those for whom antimuscarinics have proven unsuitable.

Journal

Drugs – Springer Journals

Published: Jun 4, 2018

References

  • Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment
    Gormley, EA; Lightner, DJ; Faraday, M
  • Current and future pharmacotherapy for treating overactive bladder
    Thiagamoorthy, G; Cardozo, L; Robinson, D
  • Pathophysiology of overactive bladder: current understanding
    Palmer, CJ; Choi, JM
  • Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics
    Wagg, A; Nitti, VW; Kelleher, C
  • Betanis tablet: Japanese prescribing information
  • Effect of (R)-2-(2-aminothiazol-4-yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function
    Takasu, T; Ukai, M; Sato, S
  • Urodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction
    Nitti, VW; Rosenberg, S; Mitcheson, DH
  • Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder
    Matsukawa, Y; Takai, S; Funahashi, Y
  • Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia
    Sawada, N; Nomiya, M; Hood, B
  • Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence
    Sacco, E; Bientinesi, R; Tienforti, D
  • Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3-adrenoceptor activation and α1-adrenoceptor blockade
    Alexandre, EC; Kiguti, LR; Calmasini, FB
  • Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study
    Malik, M; Gelderen, EM; Lee, JH
  • Cardiostimulant effects of mirabegron in human atrium and ventricle in vitro [abstract no. 571]
    Mo, W; Michel, M; Kaumann, A
  • An exploratory study in healthy male subjects of the mechanism of mirabegron-induced cardiovascular effects
    Gelderen, M; Stolzel, M; Meijer, J
  • Safety and tolerability of the β3-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised phase III trials and of a 1-year randomised phase III trial
    Nitti, VW; Chapple, CR; Walters, C
  • The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial
    Batista, JE; Kolbl, H; Herschorn, S
  • Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β3-adrenoceptor agonist, in overactive bladder
    Chapple, CR; Kaplan, SA; Mitcheson, D
  • Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers
    Novack, GD; Lewis, RA; Vogel, R
  • Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies
    Iitsuka, H; Tokuno, T; Amada, Y
  • Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder
    Eltink, C; Lee, J; Schaddelee, M
  • Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women
    Krauwinkel, W; Dijk, J; Schaddelee, M
  • Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy East Asian subjects
    Iitsuka, H; Gelderen, M; Katashima, M
  • Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults
    Lee, J; Zhang, W; Moy, S
  • Absorption, metabolism and excretion of [14C]mirabegron (YM178), a potent and selective β3-adrenoceptor agonist, after oral administration to healthy male volunteers
    Takusagawa, S; Lier, JJ; Suzuki, K
  • Identification of uridine 5′-diphosphate-glucuronosyltransferases responsible for the glucuronidation of mirabegron, a potent and selective β3-adrenoceptor agonist, in human liver microsomes
    Konishi, K; Tenmizu, D; Takusagawa, S
  • Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist
    Lee, J; Moy, S; Meijer, J
  • Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron
    Dickinson, J; Lewand, M; Sawamoto, T
  • Phase III study to assess long-term (52-week) safety and efficacy of mirabegron, a β3-adrenoceptor agonist, in Japanese patients with overactive bladder
    Yamaguchi, O; Ikeda, Y; Ohkawa, S
  • Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial
    Khullar, V; Amarenco, G; Angulo, JC
  • A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder
    Herschorn, S; Barkin, J; Castro-Diaz, D
  • Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia
    Kuo, HC; Lee, KS; Na, Y
  • Results of a randomized phase III trial of mirabegron in patients with overactive bladder
    Nitti, VW; Auerbach, S; Martin, N
  • Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder
    Yamaguchi, O; Marui, E; Kakizaki, H
  • Mirabegron as a treatment for overactive bladder symptoms in men: efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study (MIRACLE study) [abstract no. 273]
    Kim, HW; Shin, DG; Yoon, SJ
  • Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
    Nitti, VW; Khullar, V; Kerrebroeck, P
  • Onset of action of the β3-adrenoceptor agonist, mirabegron, in phase II and III clinical trials in patients with overactive bladder
    Chapple, CR; Nitti, VW; Khullar, V
  • Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials
    Chapple, C; Khullar, V; Nitti, VW
  • Patient-reported outcomes with the β3-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder
    Khullar, V; Amarenco, G; Angulo, JC
  • The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized phase III trials
    Castro-Diaz, D; Chapple, CR; Hakimi, Z
  • Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian phase 3 trial
    Khullar, V; Cambronero, J; Angulo, JC
  • The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients
    Wagg, A; Cardozo, L; Nitti, VW
  • Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies
    Tubaro, A; Batista, JE; Nitti, VW
  • Safety and effectiveness of mirabegron in patients with overactive bladder in a real-world clinical setting: a Japanese post-marketing study
    Nozawa, Y; Kato, D; Tabuchi, H
  • Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: interim (1-year) report from a Japanese post-marketing surveillance study
    Kato, D; Tabuchi, H; Uno, S
  • Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥ 75 years: analysis of a Japanese post-marketing study
    Yoshida, M; Nozawa, Y; Kato, D
  • Persistence and adherence to overactive bladder medications in Japan: a large nationwide real-world analysis
    Kato, D; Uno, S; Schyndle, J
  • Persistence and adherence with the new β3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada
    Wagg, A; Franks, B; Ramos, B
  • Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.
    Sussman, D; Yoshida, M; Kowalski, J
  • Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice
    Chapple, CR; Nazir, J; Hakimi, Z
  • CUA guideline on adult overactive bladder
    Corcos, J; Przydacz, M; Campeau, L
  • Persistence and compliance with medication management in the treatment of overactive bladder
    Kim, TH; Lee, KS
  • Patient-reported reasons for discontinuing overactive bladder medication
    Benner, JS; Nichol, MB; Rovner, ES
  • Profile of mirabegron in the treatment of overactive bladder: place in therapy
    Sharaf, AA; Hashim, H
  • Overactive bladder
    Wallace, KM; Drake, MJ
  • An overview of the clinical use of antimuscarinics in the treatment of overactive bladder
    Athanasopoulos, A; Giannitsas, K
  • Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder
    Andersson, KE; Sarawate, C; Kahler, KH
  • Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome
    Rosa, GM; Ferrero, S; Nitti, VW
  • Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia
    Chapple, CR; Siddiqui, E
  • Replication of Mini-Sentinel study assessing mirabegron and cardiovascular risk in non-Mini-Sentinel databases
    Simeone, JC; Nordstrom, BL; Appenteng, K
  • Efficacy and safety of add-on mirabegron vs. placebo to tamsulosin in men with overactive bladder symptoms (MATCH study) [abstract no. LBA13].
    Kakizaki, H; Lee, KS; Yamamoto, O
  • Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison
    Maman, K; Aballea, S; Nazir, J
  • Economic impact of mirabegron versus antimuscarinics for the treatment of overactive bladder in the UK
    Nazir, J; Berling, M; McCrea, C
  • Cost-effectiveness of mirabegron compared with antimuscarinic agents for the treatment of adults with overactive bladder in the United Kingdom
    Nazir, J; Maman, K; Neine, ME
  • Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom
    Aballea, S; Maman, K; Thokagevistk, K
  • Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective
    Angulo, JC; Sanchez-Ballester, F; Peral, C